SCHEMBL6906154

SCHEMBL6906154

Nc1ccccc1N(C=S)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 2/20 0.37
ALDH1A1 P00352 4/20 0.35
TSHR P16473 1/20 0.35
KIF11 P52732 3/20 0.35
MAPT P10636 3/20 0.33
GAA P10253 2/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
GFER P55789 1/20 0.33
KMT2A Q03164 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
SLC6A2 P23975 2/20 0.32
SLC6A4 P31645 2/20 0.32
SLC6A3 Q01959 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
PKM P14618 1/20 0.32
NSD2 O96028 2/20 0.32
TRPV6 Q9H1D0 1/20 0.31
PARP1 P09874 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7220722 0.84 PTGS1 (0.40) PTGS1ALDH1A1TSHRKIF11MAPT
SCHEMBL12636456 0.67 ALDH1A1 (0.46) PTGS1ALDH1A1TSHRKIF11MAPT
SCHEMBL398877 0.65 ALDH1A1 (0.58) PTGS1ALDH1A1TSHRKIF11KDM4E
Trifluoromethylbenzene SCHEMBL27720548 0.65 TSHR (0.74) ALDH1A1TSHRKIF11MAPTMEN1
SCHEMBL23020250 0.64 CYP3A4 (0.35) ALDH1A1TSHRMAPTKDM4EL3MBTL1
Hydrochloric Acid SCHEMBL2846560 0.64 ALDH1A1 (0.56) PTGS1ALDH1A1TSHRKIF11KDM4E
Fluoride SCHEMBL9251966 0.64 ALDH1A1 (0.56) PTGS1ALDH1A1TSHRKIF11KDM4E
SCHEMBL9715426 0.64 CYP3A4 (0.35) ALDH1A1TSHRMAPTGAAKDM4E
SCHEMBL2141370 0.63 ALDH1A1 (0.54) ALDH1A1TSHRKIF11MAPTGAA
SCHEMBL13445315 0.63 ALDH1A1 (0.54) ALDH1A1TSHRKIF11MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379517-A2 ABCA-1 ELEVATING COMPOUNDS AGAINST CORONARY ARTERY DISEASE OR ATHEROSCLEROSIS CV THERAPEUTICS, INC. (US) 2004-01-14 EP disclosed
US-6548548-B2 ABCA-1 elevating compounds CV THERAPEUTICS, INC. 2003-04-15 US disclosed
US-20020111364-A1 ABCA-1 elevating compounds CV THERAPEUTICS, INC. 2002-08-15 US disclosed
WO-2002046181-A2 ABCA-1 ELEVATING COMPOUNDS AGAINST CORONARY ARTERY DISEASE OR ATHEROSCLEROSIS CV THERAPEUTICS, INC. (US) 2002-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020111364-A1 ABCA-1 elevating compounds ABCD3, ABCE1, ABCB4 PTGS1 1408/4885ALDH1A1 399/4885TSHR 3699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.